GO
Loading...

AstraZeneca PLC

More

  • *Trading volumes light ahead of Labor Day holiday. NEW YORK, Aug 29- U.S. stocks closed out a strong month on a quiet note on Friday, with the S&P 500 posting a modest gain to close at a new record as the latest positive data helped extend a rally that had been briefly threatened by overseas concerns.

  • NEW YORK, Aug 29- U.S. stocks edged higher in a quiet session on Friday as the latest in a string of positive data pushed investors to extend a rally that had been briefly threatened by overseas concerns, although gains were capped ahead of an extended holiday weekend.

  • NEW YORK, Aug 29- U.S. stocks were slightly lower on Friday, with investors finding few reasons to extend a long-running rally, even as the latest economic data joined the trend of better-than-expected reports on the economy.

  • NEW YORK, Aug 29- U.S. stock index futures were modestly higher on Friday, suggesting the market's recent upswing was intact and pointing to a fourth straight week of gains for major indexes.

  • *AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Bankers and lawyers providing takeover advice said on Monday that Burger King Worldwide Inc's intention to move its tax domicile overseas through a so-called inversion deal- in this case the purchase of Canada's Tim Hortons- shouldn't be seen as a sign of a lot more deals to come.

  • There's still hunger for 'blockbuster' biotech deals Monday, 25 Aug 2014 | 10:58 AM ET
    Severin Schwan, chief executive officer Roche Holding.

    Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • *Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

  • Roche to purchase InterMune in $8.3 billion deal Sunday, 24 Aug 2014 | 12:27 PM ET

    Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • AstraZeneca says DOJ closes probe into drug trial Tuesday, 19 Aug 2014 | 12:39 PM ET

    WASHINGTON— British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The London- based drugmaker said in a statement Tuesday: " AstraZeneca has always had absolute confidence in the integrity of the PLATO trial."

  • LONDON/ MELBOURNE- The world's biggest mining company, BHP Billiton, announces plans to spin off businesses worth an estimated $16 billion, most of them acquired in a 2001 merger, to focus on its most profitable activities.

  • Early movers: HD, BHP, BAC, URBN, RDEN, LLY & more Tuesday, 19 Aug 2014 | 7:56 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • UPDATE 1-U.S. clears AstraZeneca over heart drug trial Tuesday, 19 Aug 2014 | 3:24 AM ET

    LONDON, Aug 19- The U.S. government has cleared AstraZeneca Plc over a major clinical trial used to win marketing approval for its important new heart drug Brilinta, following an investigation which had cast a shadow over its prospects.

  • U.S. clears AstraZeneca over heart drug trial Tuesday, 19 Aug 2014 | 2:31 AM ET

    LONDON, Aug 19- AstraZeneca said on Tuesday the U.S. government was closing a probe into a major clinical trial used to win marketing approval for its new heart drug Brilinta and no further action was planned.

  • LONDON, Aug 15- U.S. investors are withdrawing billions of dollars from European stocks as signs of a stalled economic recovery, compounded by the Ukraine crisis, halt the past year's scramble to buy back into the region.

  • NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.

  • UPDATE 2-Rigel eye drug fails mid-stage study, shares fall Wednesday, 13 Aug 2014 | 10:48 AM ET

    Aug 13- Rigel Pharmaceuticals Inc said it would stop testing its drug for some patients with dry eye disease after the treatment failed a mid-stage study. British drugmaker AstraZeneca Plc scrapped its licensing deal for Rigel's rheumatoid arthritis treatment in June 2013.